LABP - Landos Biopharma and Lianbio ink exclusive collaboration and license agreement

Landos Biopharma (LABP) and LianBio announce an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan and Macau) and select Asian markets.Omilancor is an oral, gut-restricted LANCL2 agonist in development for the treatment of ulcerative colitis ((UC)), Crohn’s disease ((CD)) and Eosinophilic Esophagitis ((EoE)), while NX-13 is an oral, gut-restricted NLRX1 targeting compound in development for the treatment of UC and CD.Landos will receive an upfront cash payment of $18M and is eligible to receive development and commercial milestone payments of up to $200M. It is also eligible to receive tiered low double-digit royalties based on net sales of omilancor and NX-13 in the licensed territories.Under the terms of the collaboration, LianBio will receive exclusive rights to develop and commercialize omilancor and NX-13 in Greater China, South Korea, Singapore, Thailand, Vietnam, Myanmar, Cambodia, Indonesia, and the Philippines.Landos shares up nearly 3% premarket.

For further details see:

Landos Biopharma and Lianbio ink exclusive collaboration and license agreement